A world in which the responsible application of science and technology leads to better health for people and populations. We want science to work for health. We support the responsible development and ...

The European Health Data Space Regulation has arrived but will its mandatory sharing requirement be its tour de force or Achilles’ heel? The Regulation amounts to an ambitious and laudable step ...

Inter-CeBIL is the International Collaborative Biomedical and Innovation Law program involving the law faculties at Copenhagen, Cambridge, Harvard and select other partners. PHG Foundation is ...

On Friday the High Court ruled on the case of ABC v St George’s NHS Trust (and other NHS defendants). This is a significant decision with implications for a wide range of healthcare professionals ...

The rapid development, approval and roll out of multiple vaccines against SARS-CoV-2, the virus that causes COVID-19, is an impressive achievement for science and healthcare. The virus genome was ...

Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent ...

The term ‘mainstreaming’ was first used in 2003 by the Secretary of State for Health in the context of the genetics white paper Our Inheritance, Our Future when he argued that genomics must move from ...

In a world first, the NHS has announced it is rolling out ‘blood-test first’ testing for patients with non-small cell lung cancer (NSCLC) in England. The tests have been added to the Genomic Test ...

The optimism is not unfounded. In specific, well-defined clinical scenarios, polygenic scores are beginning to demonstrate some tangible utility. For cardiovascular disease, MI-GENES, a 10-year follow ...

A recent consultation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a welcome new direction for public and patient involvement (PPI). The MHRA proposed new five-year ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.

The UK is a recognised powerhouse for genomic science and medicine. Genomics England’s 100,000 Genomes Project is the largest sequencing project of its kind in the world and, building on these ...